What Salignostics does

Salignostics Ltd is an Israel-based R&D company founded in 2016 that develops saliva-based rapid diagnostic tests. Its proprietary lateral flow immunoassay (LFA) platform addresses the three core challenges of saliva testing: low biomarker concentrations (solved via a saliva concentrator that amplifies analytes up to 10x), inhibitory agents (resolved through a patented unmasking device, including alpha-amylase removal), and inconsistent sample volumes (standardized through a metered collection handle). The platform is protected by five granted patents (EU and US) and eleven pending applications, with additional trade-secret-protected assay formulations.

The company has commercialized three CE-approved products: Salistick (the only CE-approved saliva-based pregnancy test, reporting 95% accuracy), SaliCov (an at-home COVID-19 rapid saliva test with results in 15 minutes), and Salicomb/Saliswab (a saliva collection and stabilization device for rt-PCR workflows). It operates an ISO 13485 certified manufacturing facility in Israel with capacity of one million units per month. Its pipeline covers Strep A, HIV, respiratory viruses, STIs, and three oncology indications (oral, head and neck, pancreatic cancer).

Salignostics generates revenue primarily through hardware sales of its diagnostic kits, distributed via major UK pharmacy chains (Boots, Superdrug) across 1,500+ stores, direct-to-consumer e-commerce (salistick.co.il), B2B sales of SaliCov and Salicomb to hospitals and laboratories, and potentially through technology licensing of its patented platform. Its go-to-market is hybrid: product-led growth for consumer SKUs and enterprise field sales for healthcare providers. The company maintains a presence in Israel (HQ and manufacturing), the UK (retail and distribution via Abingdon Health), Spain (European operations), and Ethiopia (HIV clinical trial), targeting consumer home-testing, healthcare providers, and laboratory diagnostics customers.

Name

Salignostics

Legal name

Salignostics Ltd

Website

https://salignostics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Salignostics is an Israel-based diagnostics company developing CE-approved saliva-based rapid tests for pregnancy, COVID-19, and other conditions. It serves consumer home-testing markets via UK retail chains and healthcare providers through its patented biomarker amplification platform.

Ownership category

akta.pro rank

Product category

Saliva-Based Rapid Diagnostic Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Home Diagnostic & Self-Test OTC Kits (HLAIADAO), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Method Development & Validation (ICH/USP) (HLAGADAB)

Keywords

• Saliva-based diagnostics
• Rapid diagnostic tests
• Pregnancy testing devices
• Point-of-care diagnostics
• Medical device manufacturing

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Test Sales: Revenue generated from sale of saliva-based diagnostic products including Salistick pregnancy test, SaliCov COVID-19 test, and Salicomb collection device. Products sold through retail channels (1,500+ stores) and direct to healthcare providers.
2. Manufacturing Services: ISO 13485 certified manufacturing facility in Israel with production capacity of 1 million units per month, serving both proprietary products and potentially contract manufacturing for partners.
3. Technology Licensing: Platform technology (patented saliva concentrator, unmasking device, metered collection) available for licensing to other diagnostic companies for various biomarker applications.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Salignostics develops and manufactures saliva-based rapid diagnostic test kits built on a proprietary lateral flow immunoassay platform that uses biomarker amplification, unmasking of inhibitory agents, and standardized sample collection to enable non-invasive testing. Its commercialized portfolio includes Salistick (the first CE-approved saliva-based pregnancy test), SaliCov (CE-approved rapid COVID-19 saliva test with 15-minute results), and Salicomb/Saliswab (CE-approved saliva collection device for rt-PCR). The company also pursues technology licensing of its patented platform components to other diagnostic developers and operates an ISO 13485 certified manufacturing facility in Israel with capacity of 1 million units per month.

Product overview

Salignostics offers a unified platform of saliva-based diagnostic products. The core portfolio includes three commercialized products: Salistick (the first CE-approved saliva-based pregnancy test), SaliCov (CE-approved COVID-19 rapid test), and Salicomb/Saliswab (CE-approved saliva collection device for lab testing). The company is developing an expanding pipeline including Strep A, HIV, respiratory viruses, and STI tests for home diagnostics, as well as oral, head & neck, and pancreatic cancer tests for medical diagnostics. All products leverage the company's proprietary saliva-based platform technology that overcomes challenges in saliva testing through biomarker amplification, unmasking agents, and standardized sample volume collection.

Differentiator

Problem solved

Functional benefit

Brands

• Salistick: The first and only CE-approved, saliva-based pregnancy test. Recognized as a 2023 TIME Magazine Best Invention, available in 1,500+ retail locations with 95% accuracy.
• SaliCov
• Salicomb/Saliswab

Products and services

• Salistick Pregnancy Test The first and only CE-approved, saliva-based rapid pregnancy test that detects pregnancy from saliva samples with 95% accuracy. Non-invasive, painless, and designed for at-home self-testing. Available in 1,500+ retail locations including Boots and Superdrug in the UK and Israeli pharmacies.
• SaliCov COVID-19 Test CE-approved, at-home saliva test for COVID-19 that provides results within 15 minutes. Designed for rapid and accessible screening at home and in clinical/point-of-care settings.
• Salicomb/Saliswab Collection Device CE-approved saliva collection and stabilization device that prepares saliva samples for rt-PCR testing and other laboratory analyses, simplifying sample preparation while ensuring stability and accuracy.

Quantifiable outcome

• 95% accuracy for Salistick pregnancy test
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• NIH RADx InitiativecoreStrategic or Co-development PartnerSalignostics was the only saliva diagnostics company to reach the final stage of NIH's RADx Initiative for COVID-19 testing, demonstrating recognition of the company's technology by a premier medical research institution.
• Hebrew UniversitycoreStrategic or Co-development PartnerFounders include VP R&D from Hebrew University. Deep research partnership with over 50 years of combined research experience and 50+ peer-reviewed publications in saliva diagnostics.
• Sheba Medical CentercoreStrategic or Co-development PartnerStrategic partnership with Israel's largest hospital for development and clinical validation of saliva diagnostic tests, including oral cancer testing.
• Abingdon HealthminorChannel Partner/ Reseller/ DistributorUK-based health company that introduced Salistick saliva pregnancy test in the UK market through retail distribution.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Mawi DNA Technologies: Biotech company developing saliva-based biosample collection and diagnostics technology. Emerging competitor in saliva sample collection and stabilization with similar focus on non-invasive diagnostics.
• Cue Health: Direct-to-consumer diagnostics company offering rapid molecular testing for respiratory health, sexual health, and other conditions. Emerging competitor in home diagnostic testing with similar business model targeting consumer convenience.
• Detect: Molecular diagnostics company developing at-home PCR-quality tests for infectious diseases. Emerging player in home diagnostics with overlapping focus on consumer-friendly rapid testing formats.

Direct peers

• OraSure Technologies: Pioneer in saliva-based diagnostics with FDA-approved oral fluid collection and testing products including HIV tests. Direct competitor in saliva diagnostics space with overlapping customer base of healthcare providers and home testing consumers.
• Swiss Precision Diagnostics (Clearblue): Manufacturer of Clearblue, the dominant brand in home pregnancy and ovulation testing. Directly competes with Salistick in the same consumer pregnancy test category with established retail presence globally.
• Church & Dwight (First Response): Owner of First Response, a leading home pregnancy and fertility test brand. Competes directly with Salistick in the retail pregnancy test category through major pharmacy and retail channels.

Broad incumbents

• Abbott Rapid Diagnostics: Global diagnostics leader with extensive rapid test portfolio including COVID-19, pregnancy, and infectious disease tests. Serves the same end markets as Salignostics through established retail and clinical channels, but with much broader product offerings.
• QuidelOrtho: Major diagnostics company with rapid test portfolio spanning infectious disease, women's health, and specialty diagnostics. Operates as broad incumbent with overlapping product categories including pregnancy and infectious disease testing.
• Hologic: Women's health diagnostics leader with strong portfolio in pregnancy, reproductive health, and infectious disease testing. Competes in similar diagnostic categories with established commercial channels and brand recognition.
• Becton Dickinson (BD): Global medical technology company with significant diagnostics and sample collection device portfolio including COVID-19 and infectious disease testing. Operates broadly across diagnostic categories overlapping with Salignostics' focus areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInil.linkedin.com/company/salignostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salignostics